Literature DB >> 8827069

Histological analysis of aggressiveness and responsiveness in Wilms' tumor.

J B Beckwith1, C E Zuppan, N G Browning, J Moksness, N E Breslow.   

Abstract

The clinical behavior and outcome for any neoplasm are determined originally by its aggressiveness. As adjuvant therapy becomes increasingly effective for that neoplasm, responsiveness to therapy assumes a larger role in determining outcome. Wilms' tumor (WT) provides instructive examples of the dissociation of aggressiveness from responsiveness. The presence of gigantic nuclei with multipolar mitotic figures (anaplasia) appears to be a marker of resistance to therapy, but not of increased aggressiveness. For this reason, anaplasia in a stage 1 WT and anaplasia confined to discrete foci within the primary tumor have no adverse prognostic significance following surgical resection. The prognostic significance of anaplasia is apparently limited to those patients in whom anaplastic cells remain following attempted surgical resection. WT with predominantly epithelial differentiation usually have a low degree of aggressiveness. In this study, 81.3% of WT with this pattern were stage 1. This feature accounts for the high cure rate associated with this pattern prior to the advent of effective adjuvant therapy. However, epithelial predominant WT that present with advanced stage disease may be quite resistant to therapy, with relapse and death rates higher than for more aggressive WT patterns. In contrast, the diffuse blastemal pattern is associated with marked aggressiveness, but with high survival rates suggesting it is usually responsive to current therapy. These features illustrate the independence of aggressiveness and responsiveness in determining outcome for some patients with cancer. Grading systems must be reevaluated with each significant change in therapy. In order to formulate rational therapy, it is important to determine whether prognostic markers are associated with aggressiveness or responsiveness.

Entities:  

Mesh:

Year:  1996        PMID: 8827069     DOI: 10.1002/(SICI)1096-911X(199611)27:5<422::AID-MPO6>3.0.CO;2-O

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  14 in total

1.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.

Authors:  Jane Lange; Susan M Peterson; Janice R Takashima; Yevgeny Grigoriev; Michael L Ritchey; Robert C Shamberger; J Bruce Beckwith; Elizabeth Perlman; Daniel M Green; Norman E Breslow
Journal:  J Urol       Date:  2011-06-17       Impact factor: 7.450

2.  Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.

Authors:  Hannah M Phelps; Mazin F Al-Jadiry; Natasha M Corbitt; Janene M Pierce; Bingshan Li; Qiang Wei; Raina R Flores; Hernan Correa; Stefania Uccini; Haydar Frangoul; Adel R Alsaadawi; Safaa A F Al-Badri; Amir F Al-Darraji; Raghad M Al-Saeed; Salma A Al-Hadad; Harold N Lovvorn Iii
Journal:  World J Pediatr       Date:  2018-08-28       Impact factor: 2.764

3.  Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.

Authors:  Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn
Journal:  Int J Cancer       Date:  2012-04-04       Impact factor: 7.396

4.  Wilms' tumorigenesis is altered by misexpression of the transcriptional co-activator, CITED1.

Authors:  Harold N Lovvorn; Scott Boyle; Genbin Shi; Yu Shyr; Marcia L Wills; Alan O Perantoni; Mark de Caestecker
Journal:  J Pediatr Surg       Date:  2007-03       Impact factor: 2.545

5.  Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.

Authors:  Simone T Sredni; Samantha Gadd; Chiang-Ching Huang; Norman Breslow; Paul Grundy; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; J Bruce Beckwith; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

6.  Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.

Authors:  Lauren N Parsons; Elizabeth A Mullen; James I Geller; Yueh-Yun Chi; Geetika Khanna; Richard D Glick; Jennifer H Aldrink; Kelly L Vallance; Yeonil Kim; Conrad V Fernandez; Jeffrey S Dome; Elizabeth J Perlman
Journal:  Cancer       Date:  2020-04-08       Impact factor: 6.860

7.  Radiation therapy for favorable histology Wilms tumor: prevention of flank recurrence did not improve survival on National Wilms Tumor Studies 3 and 4.

Authors:  Norman E Breslow; J Bruce Beckwith; Gerald M Haase; John A Kalapurakal; Michael L Ritchey; Robert C Shamberger; Patrick R M Thomas; Giulio J D'Angio; Daniel M Green
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-20       Impact factor: 7.038

8.  [Tumor size and prognosis in patients with Wilms tumor].

Authors:  Valentina Oliveira Provenzi; Rafael Fabiano Machado Rosa; Rosana Cardoso Manique Rosa; Adriana Vial Roehe; Pedro Paulo Albino dos Santos; Fabrízia Rennó Sodero Faulhaber; Ceres Andréia Vieira de Oliveira; Paulo Ricardo Gazzola Zen
Journal:  Rev Paul Pediatr       Date:  2015-01-23

9.  Wilms' Tumor in Adults-Conventional and Unconventional Presentations of a Rare Entity with a Review of Literature.

Authors:  Sujata Tripathi; Amit Mishra; Vijay C Popat; Syed Altaf Husain
Journal:  J Kidney Cancer VHL       Date:  2021-07-20

10.  Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.

Authors:  Filippo Spreafico; Sara Ciceri; Beatrice Gamba; Federica Torri; Monica Terenziani; Paola Collini; Fabio Macciardi; Paolo Radice; Daniela Perotti
Journal:  Oncotarget       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.